ULTRAGENYX PHARMACEUTICAL INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $148.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-18
- ULTRAGENYX PHARMACEUTICAL INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $148.00M, a 13.45% decline from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $171.00M, a 21.02% increase from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $141.30M, a 27.09% decline from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $193.80M, a 38.92% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $148.00M 10-K · filed 2026-02-18 | |
| 2024-12-31 | $171.00M 10-K · filed 2026-02-18 | $170.70M 10-K · filed 2025-02-19 |
| 2023-12-31 | $141.30M 10-K · filed 2025-02-19 | |
| 2022-12-31 | $193.80M 10-K · filed 2024-02-21 | |
| 2021-12-31 | $139.50M 10-K · filed 2023-02-17 | |
| 2020-12-31 | $74.30M 10-K · filed 2022-02-15 | |
| 2019-12-31 | $125.10M 10-K · filed 2021-02-12 | |
| 2018-12-31 | $57.50M 10-K · filed 2020-02-14 | |
| 2017-12-31 | $91.90M 10-K · filed 2019-02-20 | |
| 2016-12-31 | $102.90M 10-K · filed 2018-02-21 | |
| 2015-12-31 | $58.10M 10-K · filed 2017-02-17 | |
| 2014-12-31 | $25.60M 10-K · filed 2016-02-26 | |
| 2013-12-31 | $15.60M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |